The amount of data collected from patients involved in clinical trials is continuously growing. All patient characteristics are potential covariates that could be used to improve clinical trial analysis and power. However, the restricted number of patients in phases I and II studies limits the possible number of covariates included in the analyses. In this paper, we investigate the cost/benefit ratio of including covariates in the analysis of clinical trials. Within this context, we address the long-running question "What is the optimum number of covariates to include in a clinical trial?" To further improve the cost/benefit ratio of covariates, historical data can be leveraged to pre-specify the covariate weights, which can be viewed as the definition of a new composite covariate. We analyze the use of a composite covariate while estimating the treatment effect in small clinical trials. A composite covariate limits the loss of degrees of freedom and the risk of overfitting.
翻译:从参与临床试验的病人那里收集的数据数量在不断增加,所有病人的特点都是潜在的共变体,可用于改进临床试验分析和力量。但是,第一和第二阶段研究的病人人数有限,限制了分析中可能包括的共变体数量。我们在本文件中调查将共变体纳入临床试验分析的成本/效益比率。在这方面,我们处理长期问题:“在临床试验中包括的共变体的最佳数目是什么?”为了进一步改善共变体的成本/效益比率,历史数据可以用来预先确定共变数的重量,这可以视为新的复合共变体的定义。我们分析混合共变体的使用,同时估计小临床试验中的治疗效果。复合共变体限制了自由程度的丧失和过分适应的风险。